Can anything shut down the Gold rally?
Investing.com - JMP Securities has reiterated its Market Outperform rating and $21.00 price target on DBV Technologies S.A (NASDAQ:DBVT), maintaining its positive outlook on the company’s peanut allergy treatment. The stock has shown remarkable momentum, surging over 220% year-to-date, with analyst targets ranging from $7.34 to $21.45. According to InvestingPro analysis, the company currently trades near its Fair Value.
The Phase 3 VITESSE trial represents the final requirement for DBV Technologies to submit a Biologics License Application (BLA) for Viaskin Peanut, targeting peanut-allergic children aged 4-7 years, a population of approximately 390,000 in the United States.
JMP assigns a 70% probability of success for Viaskin Peanut in this age group, citing optimism based on the previous Phase 3 PEPITES study and modifications made to the VITESSE trial design.
A successful VITESSE trial would trigger approximately $180 million in additional funding through warrant exercises, which are exercisable until 30 days after positive data or April 7, 2027, whichever comes first.
DBV Technologies reported $103 million in cash as of the second quarter of 2025, with the company expecting that full warrant exercise would provide sufficient funding to launch Viaskin Peanut commercially.
In other recent news, DBV Technologies has made significant progress in its peanut allergy treatment development program. JMP Securities has maintained its Market Outperform rating for the company, reiterating a price target of $21.00. A major development is the successful initiation of the COMFORT Toddlers safety trial, which is on schedule. This trial is crucial for the company’s plan to submit a Biologics License Application for children aged 1-3 years in the second half of 2026. JMP Securities considers this trial to be a "low-risk hurdle to approval" because it does not require efficacy or adhesion endpoints to be successful. These recent developments highlight the company’s ongoing efforts to advance its treatment program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.